文献速递前列腺癌

放疗后复发性前列腺癌的挽救性前列腺切除术长期结果:CALGB 9687研究

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-11-01

中位随访91个月,2、5、10年生化无进展生存率分别为51%、39%、33%,总生存率分别为100%、89%、52%。现代手术技术仍伴随显著围手术期并发症,但SRP可能通过持久肿瘤控制使经仔细选择的患者获益。

要点

  • 放疗后SRP的10年生化无进展生存率为33%,总生存率为52%。
  • SRP后6个月和12个月尿失禁发生率分别为88%和85%。
  • SRP后6个月和12个月勃起功能障碍发生率分别为78%和82%。

核心结论

  • 现代手术技术下SRP仍伴有显著围手术期并发症,但可能为经仔细选择的患者提供持久肿瘤控制。

主要发现

  • 术后病理分期pTxN0M0中pT2占44%、pT3占54%、pT4占3%,手术切缘阳性17例,pN0占88%。
  • 2年、5年、10年生化无进展生存率分别为51%、39%、33%,总生存率分别为100%、89%、52%,中位随访91个月。
  • SRP后6个月、12个月、24个月尿失禁(≥3 pads/day)发生率分别为88%、85%、63%。
  • SRP后6个月、12个月、24个月勃起功能障碍发生率分别为78%、82%、44%。

临床怎么用

  • SRP可用于经仔细选择的放疗后复发前列腺癌患者,以追求持久肿瘤控制。
  • 术前应充分告知患者SRP后高概率的尿失禁和勃起功能障碍。

局限性

  • 研究入组时间为1997至2006年,可能不能完全反映当前手术技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate efficacy and morbidity prospectively in a contemporary multi-institutional salvage radical prostatectomy (SRP) series. METHODS: Forty-one men were enrolled between 1997 and 2006, who suffered biopsy-proven recurrent prostate cancer (CaP) after receiving ≥ 60c Gy radiation as primary treatment for cT1-2NXM0 disease. Surgical morbidity, quality of life, biochemical progression-free survival (BPFS) and overall survival (OS) were evaluated. RESULTS: Twenty-four men had undergone external beam radiotherapy, 11 brachytherapy, and six both. Median time between radiation and SRP was 64 months. Median age at SRP was 64 years. Pathologic staging revealed 44% pT2, 54% pT3, and 3% pT4. Surgical margins were positive in 17 and 88% were pN0. Twenty-two percent required intraoperative blood transfusion. Three rectal and one obturator nerve injuries occurred. Seventeen of 38 evaluable patients (45%) had urinary incontinence ( ≥ 3 pads/day) prior to SRP; 88% reported urinary incontinence at 6 months, 85% at 12 months, 63% at 24 months after SRP. Furthermore, 37% of men reported impotence prior to SRP; 78% reported impotence at 6 months, 82% at 12 months, and 44% at 24 months after SRP. The 2-, 5- and 10-year BPFS rates were 51, 39, and 33% respectively; the 2-, 5- and 10-year OS rates were 100, 89, and 52%, respectively, at median follow-up 91 months. CONCLUSIONS: Modern surgical techniques continue to be associated with significant peri-operative complication rates. Nevertheless, SRP may benefit carefully selected patients through durable oncologic control.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Mohler JL, Halabi S, Ryan ST, et al. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2018. PMID: 30385835. doi:10.1038/s41391-018-0106-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。